When you live in constant pain, the last thing you want to hear is that the treatment you so desperately need isn’t ...
Kedrion Biopharma celebrates FDA approval of Qivigy, enhancing treatment options for primary immunodeficiency while ...
Kedrion Biopharma receives US FDA approval for Qivigy to treat adults with primary humoral immunodeficiency: Barga, Italy Wednesday, October 1, 2025, 10:00 Hrs [IST] Kedrion Bioph ...
Kedrion Biopharma announced today that it has received FDA approval for QIVIGY immune globulin intravenous (human)-kthm 10% ...
Their children suddenly developed obsessive compulsive disorder and extreme food aversions. Parents are asking state ...
MedPage Today on MSN
Stopping Bispecific Appears Safe in Relapsed/Refractory Myeloma
Among 78 patients with relapsed or refractory disease, the 24-month relapse-free rate after treatment discontinuation was 68% ...
What I found to be unique about this year’s meeting was that some of the most intriguing presentations pertained to supportive care and response assessments. Here are my top 6 presentations from the ...
Joseph Mikhael, MD, and Krina K. Patel, MD, MSc, discuss considerations for CAR T-Cell therapy in multiple myeloma, including ...
Roivant Sciences surges after positive Phase 3 brepocitinib data in dermatomyositis. Despite a strong pipeline, read why I ...
Stylecaster on MSN
Selma Blair Is Going Public With Her Skincare Secret Weapon After Years of ‘Not Taking Any Pictures—It Was Really Bad’
All products and services featured are independently chosen by editors. However, StyleCaster may receive a commission on ...
Post-CAR T infection prophylaxis should follow European Hematology Association/European Society for Blood and Marrow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback